LifeArc announces seed fund investment in start-up GyreOx
The funding will support a two-year programme to develop and automate GyreOx’s proprietary drug discovery platform, MACRO.
The #COVID-19 call is now closed to new applications. Thank you for sending in your submissions, these are now unde… https://t.co/mjYUmqOPnY
LifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines
The investment will help advance studies to validate polyproxin® molecules as potential drug candidates across a range of cancers.
LifeArc and Scottish Government Chief Scientist Office launch new funding scheme to boost translational research in Scotland
Funding aims to progress strong discovery science to a point where additional substantive funding could be secured.
LifeArc marks Rare Disease Day 2020 with a call for more translational research
Translational research can turn promising science into new treatments for those with rare diseases. It’s why we…
Celebrating the International Day of Women and Girls in Science
LifeArc celebrates the UN’s International day of Women and Girls in Science, joining the call to remove any barriers that hold women back.
LifeArc and Action Medical Research launch funding call for research into rare diseases in children
£1m for translational research projects focussed on children’s rare diseases
LifeArc appoints new Chief Investment Officer (CIO)
Graham Duce appointed to the newly created role of CIO to ensure that we have a sustainable approach to income generation